Ozempic GoodRx vs Savings Card: Which Is Cheaper in 2026?

Ozempic GoodRx vs savings card: the short answer

These aren't two competing discounts on the same fill. They are different mechanisms with different eligibility gates, and a pharmacy runs exactly one payment pathway per fill.

If your commercial plan covers Ozempic for type 2 diabetes, the savings card wins in almost every case. Novo Nordisk puts the resulting cost as low as $25 a month, checked on ozempic.com on 1 September 2026. Nothing on the cash side comes close.

If you are paying cash, here is what most pages get wrong. There is no separate "GoodRx price" competing with a "NovoCare price". There is one Novo Nordisk self-pay ladder and both channels sit on it: $199 a month for the first two months on 0.25mg or 0.5mg, then $349 on 0.25mg through 1mg, and $499 on 2mg. Choosing between GoodRx and NovoCare is about fulfilment, not price.

Watch for GoodRx's older retail coupon, a different product: pharmacy and ZIP dependent, reported around $800 to $1,200 a month. A separate ladder covers the Ozempic pill at $149, $199 and $299 by strength. The real question is not "GoodRx or the card" but which of those four you are looking at.

Five programs, five eligibility gates. Figures as dated in the sections below.

How the Ozempic savings card works

Eligibility and the $25 monthly floor

The savings card is a copay reduction layered on an insurance claim that has already been approved. It doesn't create coverage and can't substitute for a prior authorization your insurer requires. You need active commercial insurance covering Ozempic plus a valid prescription. Novo Nordisk lists the resulting cost as as little as $25 a month, and the offer as valid for up to 48 months, checked on ozempic.com on 1 September 2026.

The $100 cap, and why $25 is a floor rather than a price

The card caps what it contributes: up to $100 on a 1-month fill, $200 on a 2-month, $300 on a 3-month. It also will not take you below $25 even when the full $100 is not needed. For a one-month fill the rule is your copay minus $100, or $25, whichever is higher.

Run it both ways. At a $190 copay the card contributes its $100 maximum and you pay $90, not $25. At a $115 copay the subtraction lands at $15, the floor holds, and you pay $25. Only a copay above $125 leaves you above the headline number.

So the question for an insured patient isn't whether the card exists. It's what your plan's Ozempic copay actually is. Call your insurer, get the number on your tier, subtract $100, take $25 if the result is lower, and compare that against a live GoodRx quote.

Who the card excludes

Beneficiaries of government-funded coverage are excluded by the card's own terms: Medicare, Medicaid, TRICARE, the VA, the DoD, and state pharmaceutical assistance programs. Federal anti-kickback rules sit behind that, so it is industry-wide rather than a Novo Nordisk decision, and no pharmacy can override it.

One trap catches people out. If you hold commercial insurance and any government-funded coverage at once, Novo Nordisk treats you as government-insured and the card is off the table. Federal Employees Health Benefits plans, ACA marketplace plans, and state employee health plans are not treated as government insurance here and remain eligible.

Ozempic and GoodRx: two very different prices

The Novo Nordisk self-pay ladder, reached through GoodRx

The partnership started on 18 August 2025 at a flat $499 a month. That figure is still widely quoted and is out of date. On 17 November 2025 Novo Nordisk restructured self-pay into a ladder, cutting the standard rate to $349 and adding a $199 introductory rate. GoodRx is one channel that price runs through, alongside Costco, home delivery and several telehealth providers, at more than 70,000 pharmacy locations.

Mechanically, this isn't a coupon. A discount card lowers a retail pharmacy's cash price using a benefit-manager rate, and the pharmacy's acquisition cost and margin still sit inside the number. The ladder is a manufacturer-set price. It skips a layer rather than discounting one.

One sourcing note. Novo Nordisk's own pages state the ladder directly and we read them on 1 September 2026. GoodRx blocks automated access, so the claim that GoodRx quotes those same tiers rests on Novo's 17 November 2025 announcement naming GoodRx as a participating channel, plus GoodRx's published copy, not a live quote.

The traditional GoodRx retail coupon

GoodRx's older coupon product still exists and still applies to Ozempic. Prices are set per pharmacy and per ZIP, and secondary reporting has put the pen around $800 to $1,200 a month, with GoodRx's own guidance page describing Ozempic as about $1,200 without insurance before savings. Treat that as directional, not a quote.

How to tell which one you are being quoted

Two checks settle it. Ask the pharmacist, by name, whether the fill is running the Novo Nordisk self-pay rate or a standard GoodRx coupon. Or read the number: the $199 to $499 band is the ladder, anything near four figures is the coupon.

Neither GoodRx route stacks on insurance. Each fill goes through one pathway: an insurance claim with the savings card applied to the adjudicated copay, or a cash transaction at a GoodRx price.

NovoCare direct self-pay: the same ladder, a different door

NovoCare Pharmacy is Novo Nordisk's own direct-to-patient cash channel. It does not process insurance and the savings card does not apply. Its prices are the ladder above, because it is the same manufacturer program.

Set NovoCare and GoodRx side by side and there is nothing to choose on price. Both run Novo's ladder, so a 1mg pen is $349 either way and a 2mg pen is $499 either way. Any page telling you one channel undercuts the other is comparing the current ladder against the retired flat $499.

So decide on fulfilment. NovoCare ships direct from Novo Nordisk's own pharmacy, which suits you if you want one account handling refills. GoodRx fills at a retail counter you can walk into, which wins if you want the pen today. Costco and several telehealth providers are further doors onto the same ladder, and enrolment differs by channel.

Ozempic GoodRx vs savings card by eligibility class

Which of these four situations describes you settles the question faster than any price table.

• Commercial insurance, plan covers Ozempic. Use the savings card. Get your actual copay from your insurer, subtract $100 for a 1-month fill, take $25 if the result is lower, and compare that against the self-pay ladder. In this class the card usually wins by a wide margin.
• Commercial insurance, plan excludes Ozempic or prior authorization was denied. The card runs on top of an approved claim, so with no approved claim there's nothing to reduce. You're pricing as a cash payer: find your rung on the self-pay ladder, then pick a channel on convenience.
• Medicare, Medicaid, or TRICARE. The card is unavailable to you. Unlike the weight-management picture, Part D can genuinely cover Ozempic for type 2 diabetes, so check your formulary before looking at cash routes.
• Uninsured, or paying cash by choice. Work out your rung on the ladder, choose NovoCare or GoodRx on fulfilment, and make sure the quote you get is the ladder rather than the retail coupon.

Four coverage classes, four different answers.

Medicare, Medicaid, and TRICARE

Why Ozempic's Medicare picture differs from Wegovy's

Medicare Part D excludes drugs used for weight loss from its covered-drug definition under the Social Security Act, carried through in the CMS Prescription Drug Benefit Manual. That exclusion is tied to the indication, not the molecule. Ozempic is approved for type 2 diabetes, so it sits outside it, and Part D plans can cover it subject to formulary and prior authorization rules.

Part D beneficiaries also get the Inflation Reduction Act redesign, which put a ceiling on annual out-of-pocket Part D spending. That ceiling is indexed and moves each year: $2,000 when it took effect on 1 January 2025, $2,100 in 2026 and $2,400 in 2027 (medicare.gov, checked 2 October 2026). It applies across all your covered Part D drugs, not to Ozempic alone, and it is why a Part D route can beat any cash program over a full year.

TRICARE covers the drug, not the card

Two separate questions here, and blurring them is the most common error on this topic.

The savings card excludes TRICARE beneficiaries, alongside every other form of government-funded coverage. That is settled and there is no workaround.

TRICARE's coverage of Ozempic itself is a different matter, and the answer is yes for type 2 diabetes. It sits on TRICARE's nonpreferred formulary tier, so it needs prior authorization plus a medical-necessity form and carries the higher nonpreferred copay. Checked against TRICARE's official pharmacy guidance on 1 September 2026. Do not read "the card excludes TRICARE" as "TRICARE excludes Ozempic". Those are unrelated facts, and the second is false.

Medicaid

Medicaid coverage is set state by state. The diabetes indication makes Ozempic a far easier case than a weight-management product, but whether it sits on your state's preferred drug list is a question for your state Medicaid program.

A 2027 list price cut is coming, but not yet

On 24 February 2026, Novo Nordisk announced a uniform list price of $675 a month across Wegovy, Ozempic and Rybelsus, effective 1 January 2027. For Ozempic that is a cut of about 34% from $1,027.51. One Ozempic pen is one month's supply, so the per-pen and per-month figures line up directly.

It changes nothing you can act on today. List price is the wholesale figure insurers and benefit managers negotiate against, and it matters most if your out-of-pocket cost is calculated off it. Novo Nordisk stated explicitly that the change does not affect direct-to-consumer self-pay pricing, so no rung of the ladder is scheduled to move. Treat the 2027 number as a calendar note.